Citable filing context
PODD's research view summarizes recent SEC filing context, starting with earnings from Aug 5, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 5, 2026 | earnings | Insulet reported second quarter 2026 revenue of $801.7 million, an increase of 23.5% year-over-year. |
| Jun 25, 2026 | management_change | Insulet appointed Jonathan J. Mazelsky as a Class II director, effective July 1, 2026. |
| May 26, 2026 | other | Insulet announced a voluntary medical device correction for ~7 million Omnipod Pods, with expected costs up to $50 million. |
| Aug 5, 2026 | Guidance: international_omnipod_revenue_growth | 28.00 to 30.00 |
| Aug 5, 2026 | Guidance: international_omnipod_revenue_growth | 30.00 to 32.00 |
| Aug 5, 2026 | Guidance: total_revenue_growth | 20.00 to 22.00 |
| Aug 5, 2026 | mda_quarterly | Insulet Corporation continues to drive growth through its Omnipod insulin delivery platform, specifically the Omnipod 5 automated insulin delivery system. Total revenue for the six months ended June 30, 2026, reached $1.56 billion, a 28.4% increase year-over-year, fueled by a growing customer base and international expansion into markets like the Middle East and Spain. While U.S. revenue remains the primary driver, international performance showed significant momentum with 46.3% growth. Operational challenges include $41 million in net charges recorded during the first half of 2026 related to two voluntary medical device corrections involving cannula tears. These corrections, alongside inventory obsolescence, pressured gross margins. The company is mitigating these risks by investing in automated inspection systems and expanding manufacturing capacity in Costa Rica. Research and development spending rose to $177.8 million, reflecting ongoing development of the Omnipod 6 and a closed-loop system for type 2 diabetes. Liquidity remains stable, though free cash flow declined to $145.4 million due to higher capital expenditures and working capital outflows. The company maintains a strong balance sheet, recently executing $300 million in share repurchases, and continues to navigate complex global tax environments, including OECD Pillar Two requirements. |
| May 6, 2026 | mda_quarterly | Total revenue for the first quarter of 2026 rose 33.9% to $761.7 million, primarily driven by volume growth of the Omnipod 5 automated insulin delivery system. U.S. revenue increased 28.3% to $515.6 million, while international revenue grew 59.4% to $242.9 million, supported by a February 2026 launch in five Middle East countries. Gross margin declined 240 basis points to 69.5%, pressured by inventory obsolescence and a voluntary medical device correction estimated to cost $30 million. Research and development expenses increased 50.6% to $89.7 million to fund the development of Omnipod 6 and a fully closed-loop system for type 2 diabetes, with a 510(k) submission planned for 2027. The company is also integrating Omnipod 5 with Abbott’s Libre 3 Plus sensor. Adjusted EBITDA grew to $181.7 million, and free cash flow increased to $89.5 million. Strategic capital investments include a new manufacturing plant in Costa Rica to support global scaling. Financing activities were highlighted by the completion of a $300 million accelerated share repurchase program. Conversely, drug delivery revenue from Amgen declined significantly to $3.3 million. |
Source: SEC EDGAR filing text and events; period Aug 5, 2026; filed Aug 5, 2026.
PODD company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.